1 |
Murphy AR, Campo H, Kim JJ. Strategies for modelling endometrial diseases. Nat Rev Endocrinol 2022;18:727-43. [PMID: 36050476 DOI: 10.1038/s41574-022-00725-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
2 |
Navaridas R, Vidal-sabanés M, Ruiz-mitjana A, Perramon-güell A, Megino-luque C, Llobet-navas D, Matias-guiu X, Egea J, Encinas M, Bardia L, Colombelli J, Dolcet X. Transient and DNA-free in vivo CRISPR/Cas9 genome edition for flexible modelling of endometrial carcinogenesis.. [DOI: 10.1101/2022.06.17.496593] [Reference Citation Analysis]
|
3 |
Sahoo SS, Ramanand SG, Gao Y, Abbas A, Kumar A, Cuevas IC, Li HD, Aguilar M, Xing C, Mani RS, Castrillon DH. FOXA2 suppresses endometrial carcinogenesis and epithelial-mesenchymal transition by regulating enhancer activity. J Clin Invest 2022;132:e157574. [PMID: 35703180 DOI: 10.1172/JCI157574] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|